Acute Respiratory Distress Syndrome Secondary to Enterovirus-Human-Rhinovirus Infection in an Adult

Khizar Hamid 1, Mohammad Ali 1, Joe Devasahayam 2

1. Internal Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, USA
2. Pulmonary Critical Care, Avera McKennan Hospital and University Health Center, Sioux Falls, USA

Corresponding author: Khizar Hamid, khizar.hamid@usd.edu

Abstract

Enterovirus-human-rhinovirus (EV-HRV) are small RNA viruses that are airborne and can spread by direct contact or fomites and usually cause the common cold, asthma and chronic obstructive pulmonary disease exacerbation. EV-HRV-associated acute respiratory distress syndrome (ARDS) is common in children but is a rare cause of ARDS in adults. ARDS is defined according to the Berlin criteria and can be mild, moderate or severe depending on the PaO2 to FIO2 ratio. We report a case of a 70-year-old female with cardiac comorbidities, emphysema, second-hand smoking of 25 years, on methotrexate for rheumatoid arthritis presenting with ARDS secondary to EV-HRV infection. Despite initial treatment with appropriate antibiotics, steroids, low tidal volume mechanical ventilation, rescue maneuvers such as ventilation in prone positioning, paralyses, and inhaled nitric oxide, she passed away. EV-HRV causes upper respiratory tract infections but causes cytokine releases such as IL-1, IL-6, and IL-8 in the lower respiratory tract and in the blood which can cause ARDS. Very few cases of EV-HRV ARDS in immunocompetent adults are reported in the literature. Female sex is also associated with EV-HRV ARDS. No antiviral therapy exists for patients critically ill with EV-HRV; however, one case of successful treatment with high-dose intravenous vitamin C (HIVC) is reported in the literature. EV-HRV is one of the most common viruses identified in patients admitted with viral pneumonia in the intensive care unit. It should not be forgotten as a cause of ARDS.

Keywords: acute respiratory distress syndrome (ARDS), COVID-19, community acquired pneumonia, viral infection, medical intensive care unit (MICU)

Introduction

Enterovirus-human-rhinovirus (EV-HRV) belongs to the Picornavirus family. These are small, nonenveloped, icosahedral viruses with positive-strand RNA genomes. Picornaviruses, which infect humans and cause high morbidity, belong to the Enterovirus genus [1]. These can be airborne and can spread via direct contact or contact with fomites [2]. EV-HRV are responsible for the common cold and are the usual culprits for asthma and chronic obstructive pulmonary disease exacerbation [3]. They mainly cause infections in the pediatric population but in adults the disease course is variable [4]. EV-HRV is a rare cause of acute respiratory distress syndrome (ARDS), with EV-HRV ARDS being more commonly seen in immunocompromised and elderly patients [4,5].

Case Presentation

A 70-year-old Caucasian female unvaccinated for COVID-19 was admitted to the hospital with complaints of shortness of breath for eight days. Her past medical history included chronic atrial fibrillation on sotalol with a pacemaker in situ, coronary artery disease treated with coronary artery bypass grafting, rheumatoid arthritis on methotrexate, hypertension, hyperlipidemia, hypothyroidism, obstructive sleep apnea on continuous positive airway pressure therapy, chronic kidney disease stage 3b and history of gastrointestinal bleeding (GIB). Before a scheduled endoscopy for GIB evaluation, she was found to have an oxygen saturation of 65% prompting her admission. She was noted to be morbidly obese with a BMI of 42 kg/m2 requiring 3L of oxygen via nasal cannula (NC) to maintain an oxygen saturation of 95%. Lab work was unremarkable. She was a nonsmoker but her husband was a smoker for 25 years quitting 15 years ago. A computed tomographic angiogram (CTA) of the chest was done which excluded pulmonary embolism (PE) but revealed severe emphysema and multifocal bilateral atypical pneumonia (PNA) (Figure 1). Testing for COVID-19, MRSA PCR, urine Legionella, and urine streptococcal antigen returned negative. A comprehensive respiratory panel was obtained from the nasopharynx returning positive for enterovirus. An echocardiogram was done which revealed an ejection fraction of 65%-70%. Empiric treatment with antibiotics was initiated but her oxygen requirements continued to rise eventually requiring constant bilevel positive airway pressure support. Fungal serologies, ANA, anti-myeloperoxidase antibody, and serine protease 3 antibody testing also returned negative. She completed five days of appropriate antibiotics and was started on 40 mg methylprednisolone twice a day however her oxygen requirements increased requiring...
intubation and mechanical ventilation. A bronchoscopy was performed which was unremarkable and repeat COVID-19 testing, fungal testing, and cultures from the bronchoalveolar lavage (BAL) resulted in negative. Her steroids were increased to 1 g methylprednisolone for three days which was tapered to 40 mg twice a day with little improvement. Dapsone 100 mg per day was initiated for Pneumocystis jirovecii prophylaxis. Hypersensitivity pneumonitis testing from the BAL returned positive for Aureobasidium pullulans. Despite the use of rescue maneuvers such as frequent prone position ventilation and inhaled nitric oxide (iNO), her PaO2/FiO2 ratio (P/F) remained persistently below 150 mmHg. Aggressive diuresis and paralysis with cisatracurium for 48 hours did not decrease her FiO2 requirements. She was on the ventilator for 15 days and had been in the hospital for 30 days. Due to her continued decline and lack of improvement, the family elected for comfort cares, and the patient was extubated and passed away.

**FIGURE 1:** CTA PE showing severe emphysematous changes (yellow arrows) and extensive consolidation seen bilaterally. The patient was a second-hand smoker for 25 years. Her partner stopped smoking 15 years before the presentation.

CTA PE - computed tomographic angiogram pulmonary embolism

**Discussion**

Berlin criteria can be used to define ARDS according to P/F. It can be categorized as mild (P/F >200 to <300 mmHg), moderate (P/F > 100 to <200 mmHg), or severe (P/F <100 mmHg) [6]. Seasonal viruses are identified in 22-36% of community-acquired PNA patients requiring intensive care unit (ICU) admissions with Influenza and EV-HRV being most commonly detected [5]. EV-HRV commonly causes upper respiratory tract infections in children and adults; however, it also causes cytokine release such as IL-1, IL-6, and IL-8 in the lower respiratory tract and blood which can cause ARDS and viral PNA [4,5]. ARDS due to EV-HRV infection is common in the pediatric population, especially in patients with asthma; however, it is a rare cause of ARDS in adults [4]. Interestingly, most EV-HRV ARDS are documented in females [2-4]. Severe EV-HRV-associated PNA is more likely to be seen in immunocompromised individuals [7]. Very few cases of EV-HRV-associated ARDS in immunocompetent hosts have been reported in the literature [2]. Our patient’s history of treatment with methotrexate and its adverse pulmonary effects and immunosuppression could have predisposed her to severe EV-HRV infection [8]. Her emphysematous changes noted on CTA could have also predisposed her to more severe disease.

There are no specific treatment approaches for EV-HRV-associated ARDS. The usual care of ARDS including low tidal volume ventilation of 6 mL/kg should be employed [9]. Prone position ventilation has also been shown to improve severe ARDS mortality [10]. Our patient had temporary improvements in FiO2 with prone position ventilation; however, upon supination, her FiO2 requirements would gradually increase to previous levels. Inhaled nitric oxide (iNO) was also utilized with transient improvement in oxygenation. iNO has been shown to improve oxygenation levels temporarily but it has not shown any mortality benefit and can cause renal impairment [11]. It can be utilized as rescue therapy to improve oxygenation [12]. Dexamethasone (6 mg) has been shown to improve mortality in COVID-19 infection of patients requiring oxygen or mechanical
ventilation [13]. Another trial revealed that 20 mg of dexamethasone for five days followed by 10 mg of dexamethasone for five days improves the duration of mechanical ventilation and overall mortality in moderate to severe ARDS [14]. These benefits could also possibly apply to ARDS due to EV-HRV. Currently, there is no antiviral therapy for critically ill adults with EV-HRV PNA [5]. Fowler III et al. reported successfully treating EV-HRV ARDS with high-dose intravenous vitamin C (HIVC) [15]. However, more research needs to be done to identify vitamin C as a therapeutic option. Clinical trials of HIVC for severe COVID-19 infection are underway, which might shed some insight into the treatment of other severe pulmonary viral infections with HIVC [16]. The capsid-binding anti-HRV agent pleconaril reduced the duration of uncomplicated HRV infection by one day but was not approved due to concerning drug-drug interactions. Intranasal recombinant interferon alfa-2b is effective for postexposure prophylaxis but not for established infection. More research needs to be done for antiviral treatments for patients critically ill with EV-HRV [5].

Conclusions
EV-HRV, which commonly causes upper respiratory tract infections in the pediatric population, can occasionally cause severe ARDS in adults. It usually causes this in immunocompromised patients but can also cause it in immunocompetent individuals. Limited data show female sex is associated with EV-HRV ARDS. The treatment approach is similar to ARDS from other causes, such as low tidal volume ventilation, prone position ventilation, and steroids. No antiviral therapy exists for critically ill patients infected with EV-HRV. One case of successful treatment with HIVC is reported in the literature. More research needs to be done to identify antiviral treatments for critically ill patients with EV-HRV ARDS. ARDS due to other viruses should continue to be on the differential during the COVID-19 pandemic.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Liu Y, Hill MG, Klose T, et al.: Atomic structure of a rhinovirus C, a virus species linked to severe childhood asthma. Proc Natl Acad Sci U S A. 2016, 113:9979-9002. 10.1073/pnas.1606951113
2. Nga S, Pervaiz S, Avula A, Chalhoub M: Rhinovirus-induced rapidly progressing acute respiratory distress syndrome in an immunocompetent host. Cureus. 2019, 11:e3997. 10.7759/cureus.3997
3. Abdelnabi R, Geraets JA, Ma Y, et al.: A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses. PLoS Biol. 2019, 17:e3000281. 10.1534/journal.pbio.3000281
4. Soni P, Rai A, Aggarwal N, Kambhalkar S, Yoon T, Kuperf Y: Enterovirus-human rhinovirus: a rare cause of acute respiratory distress syndrome. J Investig Med High Impact Case Rep. 2017, 5:2324709617728526. 10.1177/2324709617728526
5. Shah RD, Wunderink RG: Viral pneumonia and acute respiratory distress syndrome. Clin Chest Med. 2017, 38:115-25. 10.1016/j.ccm.2016.11.015
6. Ranieri VM, Rubenfeld GD, Thompson BT, et al.: Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012, 307:2526-53. 10.1001/jama.2012.5649
7. Choi SH, Huh JW, Hong SB, et al.: Clinical characteristics and outcomes of severe rhinovirus-associated pneumonia identified by bronchoscopic bronchoalveolar lavage in adults: comparison with severe influenza virus-associated pneumonia. J Clin Virol. 2015, 62:41-7. 10.1016/j.jcv.2014.11.010
8. McKeendy RJ, Dale P: Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol. 1993, 20:1850-6.
9. Malhotra A: Low-tidal-volume ventilation in the acute respiratory distress syndrome. N Engl J Med. 2007, 357:1113-20. 10.1056/NEJMct074213
10. Scholten EL, Beiter J, Prick GK, Malhotra A: Treatment of ARDS with prone positioning. Chest. 2017, 151:215-24. 10.1016/j.chest.2016.06.032
11. Gebisstor F, Karam O, Witterslev J, Afsari A: Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev. 2016, CD002787. 10.1002/14651858.CD002787.pub5
12. Monsalve-Naharro JA, Domingo-Chiva E, García Castillo S, Cuesta-Montero J, Jiménez-Vizuete M: Inhaled nitric oxide in adult patients with acute respiratory distress syndrome. Farm Hosp. 2017, 41:292-312. 10.1016/j.fch.2017.04.008
13. Horby P, Lim WS, Emberson JR, et al.: Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021, 384:695-704. 10.1056/NEJMoa2114356
14. Villar J, Ferrando C, Martínez D, et al.: dexamethasone in ARDS network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020, 8:267-6. 10.1016/s2213-2680(19)30417-5
15. Fowler III AA, Kim C, Lepler L, et al.: Intravenous vitamin C as adjunctive therapy for enterovirus/rhinovirus
induced acute respiratory distress syndrome. World J Crit Care Med. 2017, 6:85-90. 10.5492/wjccm.v6.i1.85
16. Liu F, Zhu Y, Zhang J, Li Y, Peng Z: Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial. BMJ Open. 2020, 10:e039519. 10.1136/bmjopen-2020-039519